These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7916020)

  • 1. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
    Abelson MB; George MA; Schaefer K; Smith LM
    J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA; Leahy C; Krenzer KL
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model.
    Abelson MB; George MA; Smith LM
    Ophthalmology; 1995 Feb; 102(2):310-6. PubMed ID: 7862419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.
    Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E
    Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
    Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
    Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
    Verin P; Easty DL; Secchi A; Ciprandi G; Partouche P; Nemeth-Wasmer G; Brancato R; Harrisberg CJ; Estivin-Ebrardt C; Coster DJ; Apel AJ; Coroneo MT; Knorr M; Carmichael TR; Kent-Smith BT; Abrantes P; Leonardi A; Cerqueti PM; Modorati G; Martinez M
    Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
    Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
    Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of levocabastine in conjunctival provocation studies.
    Janssens M
    Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
    Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
    Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group.
    Secchi A; Leonardi A; Discepola M; Deschenes J; Abelson MB
    Acta Ophthalmol Scand Suppl; 2000; (230):48-51. PubMed ID: 11057351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone].
    Richard C; Bibas P; Lablache-Combier M; Allaire C
    J Fr Ophtalmol; 2005 Mar; 28(3):244-50. PubMed ID: 15883488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB; Spitalny L
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New trends in the treatment of allergic conjunctivitis.
    Parys W; Blockhuys S; Janssens M
    Doc Ophthalmol; 1992; 82(4):353-60. PubMed ID: 1363981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB; Lanier RQ
    Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis.
    Stokes TC; Feinberg G
    Clin Exp Allergy; 1993 Sep; 23(9):791-4. PubMed ID: 10779311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group.
    Richard C; Trinquand C; Bloch-Michel E
    Eur J Ophthalmol; 1998; 8(4):207-16. PubMed ID: 9891891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.